The Cancer Foundation For The World » Lung Cancer

New Data From Phase III Lung Cancer Trial Show VeriStrat(R) Identifies Patients Likely To Respond To Erlotinib

Jeff Daas — Sun, 02 May 2010 03:01:48 +0000

Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, a commonly prescribed oral therapy for advanced non-small cell lung cancer (NSCLC)…
Read Full Article

Targeting Of Anti-Angiogenesis Treatment Promised By Spanish Gene Expression Data

Jeff Daas — Sun, 02 May 2010 03:01:37 +0000

Analyzing the expression of particular genes in lung cancers could soon allow researchers to identify groups of patients who are likely to benefit most from treatment with angiogenesis-inhibitor drugs, a Spanish team reports. Dr Eloisa Jantus from the General University Hospital of Valencia reports new findings from an analysis of 135 lung cancer specimens…
Read Full Article

A New Drug Target In Lung Cancer – CXCR4

Jeff Daas — Sun, 02 May 2010 03:01:32 +0000

Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy…
Read Full Article

A New Drug Target In Lung Cancer – CXCR4

Jeff Daas — Sat, 01 May 2010 11:03:24 +0000

Best Care For The Oldest Lung Cancer Patients

Jeff Daas — Sat, 01 May 2010 11:03:20 +0000

Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce…
Read Full Article

Rosetta Genomics Announces Publication Of Study On MicroRNA Expression For Lung Tumor Classification

Jeff Daas — Sat, 01 May 2010 11:03:16 +0000

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces the publication of a study showing microRNA expression differentiates between primary lung tumors and metastases to the lung…
Read Full Article

OSI Pharmaceuticals Announces That Tarceva(R) Received Approval In The European Union For Maintenance Use In Advanced Non-Small Cell Lung Cancer

Jeff Daas — Sat, 01 May 2010 11:03:08 +0000

OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the European Commission for Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell lung cancer (NSCLC) whose disease remains largely unchanged (stable disease) after platinum-based initial chemotherapy…
Read Full Article

A Polymer Pill To Improve Lung Cancer Diagnosis

Jeff Daas — Sat, 01 May 2010 11:03:05 +0000

Doctors may soon be able to diagnose lung cancer more effectively thanks to research performed at the National Institute of Standards and Technology (NIST), where scientists have found ways both to increase the accuracy of computed tomography (CT) scans and to lessen the amount of time necessary to perceive telltale changes in lung tissue…
Read Full Article

A Polymer Pill To Improve Lung Cancer Diagnosis

Jeff Daas — Fri, 30 Apr 2010 12:00:06 +0000

A Polymer Pill To Improve Lung Cancer Diagnosis

Jeff Daas — Fri, 30 Apr 2010 11:00:08 +0000